Clinical trial
Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular…
NCT00159250 · Imperial College London, Other · Completed
Key facts
| NCT number | NCT00159250 |
|---|---|
| Title | Safety and Efficacy Study of Antisense Oligonucleotides in Duchenne Muscular Dystrophy |
| Official title | Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: A Phase I/II Clinical Trial Using AVI-4658 |
| Lead sponsor | Imperial College London, Other |
| Collaborators | Department of Health, United Kingdom Sarepta Therapeutics, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Duchenne Muscular Dystrophy |
| Intervention type | Drug |
| Interventions | AVI-4658 (PMO) |
| Enrollment | 7 |
| Start date | Oct 26, 2007 |
| Primary completion | Dec 1, 2008 |
| Completion | Mar 31, 2009 |
| First posted | Sep 12, 2005 |
| Last update posted | Dec 5, 2019 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: